Karyopharm Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$381.7M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Karyopharm Therapeutics's estimated annual revenue is currently $118.7M per year.(i)
  • Karyopharm Therapeutics received $Undisclosed in venture funding in January 2015.
  • Karyopharm Therapeutics's estimated revenue per employee is $224,291
  • Karyopharm Therapeutics's total funding is $381.7M.
  • Karyopharm Therapeutics's current valuation is $607.4M. (January 2022)

Employee Data

  • Karyopharm Therapeutics has 529 Employees.(i)
  • Karyopharm Therapeutics grew their employee count by 2% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$413.3M344-2%$634MN/A
#2
$49.6M247-6%N/AN/A
#3
$10.7M53130%N/AN/A
#4
$20.1M10023%$113MN/A
#5
$4M48118%N/AN/A
#6
$1.8M4063%$538MN/A
#7
$40.2M200-11%N/AN/A
#8
$11.6M192-14%$506.4MN/A
#9
$3.7M4588%N/AN/A
#10
$4360M45081175%N/AN/A

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. For more information, please visit www.karyopharm.com

keywords:Biotechnology,Cleantech,Healthcare,Marketing,Pharmaceuticals,Wind Power

$381.7M

Total Funding

529

Number of Employees

$118.7M

Revenue (est)

2%

Employee Growth %

$607.4M

Valuation

N/A

Accelerator

Karyopharm Therapeutics News

2022-04-20 - Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Expected to Post Quarterly Sales of $35.14 Million

Six analysts have made estimates for Karyopharm Therapeutics' earnings. The highest sales estimate is $37.23 million and the lowest is $31.33...

2022-04-17 - Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Sees Large ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Sees Large Increase in Short Interest. Posted by admin on Apr 19th, 2022.

2022-03-30 - Karyopharm Therapeutics Reports Inducement Grants Under ...

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding,...

2021-11-03 - Karyopharm Reports Strong Third Quarter 2021 Financial Results and Provides Business Highlights

NEWTON, Mass., Nov. 3, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended September 30, 2021 and provided business highlights. "Driven by acceleratio ...

2021-10-21 - Karyopharm Therapeutics : Announces Dosing of First Patient in a Phase 2 Study Investigating Oral Eltanexor in HMA Refractory Myelodysplastic Syndrome

NEWTON, Mass., Oct. 21, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced dosing of the first patient in the Phase 2 expansion of an ongoing open-label Phase 1/2 study investigating eltane ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$111.8M550-4%$10.9M
#2
$151.5M55149%N/A
#3
$35M5707%N/A
#4
$114.5M64413%$122M
#5
$146.9M653N/AN/A

Karyopharm Therapeutics Funding

DateAmountRoundLead InvestorsReference
2011-11-03$10.0MA2Chione LtdArticle
2013-05-14$20.5MUndisclosedArticle
2013-05-21$48.2MBDelphi VenturesArticle
2013-08-02$19.0MBArticle
2015-01-07$UndisclosedUndisclosedBofA Merrill LynchArticle